索引于
  • 打开 J 门
  • Genamics 期刊搜索
  • 学术钥匙
  • 期刊目录
  • 研究圣经
  • 中国知网(CNKI)
  • 西马戈
  • 乌尔里希的期刊目录
  • 电子期刊图书馆
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-WorldCat
  • SWB 在线目录
  • 虚拟生物学图书馆 (vifabio)
  • 普布隆斯
  • 米亚尔
  • 科学索引服务 (SIS)
  • 欧洲酒吧
  • 谷歌学术
分享此页面
期刊传单
Flyer image

抽象的

Novel Nanosized Gd3+-ALGD-G2-C595: In vivo Dual Selective MUC-1 Positive Tumor Molecular MR Imaging and Therapeutic Agent

Mehdi Mirzaei, Mohammadali Mohagheghi, Daryoush Shahbazi-Gahrouei and Alireza Khatami

Scope of this study is to synthesize a nano-dendrimer and its conjugate with C595 MAb against breast cancer cell, followed by its chelating agent with Gd3+. At the end, its use as a dual nanosized probe for detection and treatment was investigated. Anti-MUC-1 MAb C595 was coupled to a biodegradable biocompatible anionic linear globular dendrimer, ALGDG2, Poly ethylene glycol PEG core and citric acid shell followed by loading with Gd3+ to make novel MR imaging contrast agents. Anticancer effects and MR imaging parameters of the prepared nanoconjugate was investigated in vitro: cell toxicity, apoptosis and TNF-alpha, hemolysis, LDH evaluations as well as toxicity, biodistribution and MR imaging of cancer place were investigated. Results showed good tumor accumulation and detection, no in vivo toxicity, and potential selective anti-breast cancer activity. In conclusion, findings of this study showed that Gd3+-ALGDG2-C595 nano-probe is potentially both, a selective breast molecular imaging tool as well as a therapeutic agent. Further, subsequent clinical trials appear warranted.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证